Aprogen Biologics Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 27,074.58 million compared to KRW 15,226.84 million a year ago. Net loss was KRW 17,712.94 million compared to net income of KRW 3,092.06 million a year ago. Basic loss per share from continuing operations was KRW 280 compared to basic earnings per share from continuing operations of KRW 80 a year ago. Diluted loss per share from continuing operations was KRW 280 compared to diluted earnings per share from continuing operations of KRW 80 a year ago. Basic loss per share was KRW 280 compared to basic earnings per share of KRW 80 a year ago.
For the six months, sales was KRW 702.27 million compared to KRW 24.92 million a year ago. Net loss was KRW 16,609.96 million compared to net income of KRW 5,918.22 million a year ago. Basic loss per share from continuing operations was KRW 280 compared to basic earnings per share from continuing operations of KRW 150 a year ago. Diluted loss per share from continuing operations was KRW 280 compared to diluted earnings per share from continuing operations of KRW 150 a year ago. Basic loss per share was KRW 280 compared to basic earnings per share of KRW 150 a year ago.